Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, has today announced the launch of hVIVO COVID Clear Test, the Company’s antibody testing service, following the successful completion of installation, testing and training.
The antibody tests, which utilise the Quotient MosaiQ™ system and MosaiQ COVID-19 Antibody Microarray, offer best in class COVID-19 antibody testing performance and will require a full blood draw. hVIVO COVID Clear Test will be offered to large employer groups and channel partners including GP networks, nursing services, health clinics and private hospitals. Samples will be tested in the Company’s London laboratory with results returned within 48 hours.
The Company is hosting a press event at its clinic in East London at 11am today details of which can be found at: https://hvivo.com/news-media/companynews/.
Cathal Friel, Executive Chairman of Open Orphan, said:
“hVIVO is a world class company with best in class scientists and facilities. We are very excited to be offering this service and I am confident our work will help large companies and clinics in the UK test their staff and patients to ensure the safety of all employees. I look forward to updating everyone on our progress in due course.”
Franz Walt, Chief Executive Officer, Quotient, said:
“Antibody testing is crucial for guidance on immunity, development of vaccinations and potential revaccinations, as well as helping to answer outstanding epidemiological questions about the spread of the virus. We are incredibly proud to be collaborating with hVIVO and Open Orphan in this project and can assure them that we will provide top of the line services alongside our excellent products.”
